Multicellular living organisms and unmodified parts thereof and – Nonhuman animal – Transgenic nonhuman animal
Reexamination Certificate
1995-06-07
2001-02-06
Crouch, Deborah (Department: 1632)
Multicellular living organisms and unmodified parts thereof and
Nonhuman animal
Transgenic nonhuman animal
C800S003000, C800S012000
Reexamination Certificate
active
06184435
ABSTRACT:
BACKGROUND OF THE INVENTION
The present invention relates to a method for screening for risk of Alzheimer's disease in a patient, and to a transgenic mammal carrying a mutated human gene associated with the development of Alzheimer's disease.
Alzheimer's disease is a form of localized amyloidosis characterized by cerebral cortical amyloid plaques, neurofibrillary tangles, and amyloid deposits within the walls of leptomeningeal vessels. Although most cases of Alzheimer's disease are sporadic, kindreds with autosomal dominant inheritance of the syndrome suggest that a single mutation may be important in pathogenesis.
Hereditary or familial Alzheimer's disease is an autosomal dominant form of localized amyloidosis. Patients with hereditary Alzheimer's disease typically develop three pathologic lesions: (i) senile plaques in the cerebral cortex characterized by a central amyloid core surrounded by dystrophic neurites; (ii) neurofibrillary tangles; and (iii) congophilic angiopathy of the leptomeningeal vessels. The amyloid deposits in the senile plaques and in the blood vessel walls contain a fibril subunit protein of 39 to 43 amino acid residues [See, G. G. Glenner and C. W. Wong,
Biochem. Biophys., Res. Commun.,
120, p. 885 (1984)], which is a portion of the carboxyl terminus of the amyloid precursor protein (APP). Sequence analysis of cDNA clones of APP has shown that there are multiple forms of mRNA which are the result of alternate splicing of a transcript from a single gene. See, J. Kang et al.,
Nature,
325, p. 733 (1987); P. Ponte et al., Ibid, 331, p. 525 (1988); R. E. Tanzi et al., Ibid, p. 528; N. Kitaguchi, Y. Takahashi, Y. Tokushima, S. Shiojiri, H. Ito, Ibid, p. 530; N. Kitaguchi et al.,
Biochim. Biophys. Acta,
1039, p. 105 (1990); and S. Yoshikai, H. Sasaki, K. Doh-ura, H. Furuya, Y. Sasaki,
Gene
87, p. 257 (1990). Although the sequence of the APP gene from some patients with either sporadic or familial Alzheimer's disease is normal [See, D. Goldgaber, M. I. Lerman, O. W. McBridde, U. Saffotti, D. C. Gajdusek,
Science
235, p. 887 (1987); R. E. Tanzi et al., ibid, p. 880; N. K. Robakis, N. Ramakrishna, G. Wolfe, H. M. Wisniewski,
Proc. Natl. Acad. Sci. U.S.A.,
84, p. 4190 (1987); H. G. Lemaire et al.,
Nucleic Acids. Res.
17, p. 51 (1989); and M. P. Vitek et al., Mol.
Brain Res.
4, p. 121 (1988)], a cytosine to thymine missense mutation in the membrane-spanning domain of the APP gene (causing a valine to isoleucine change in the corresponding amino acid sequence of the encoded APP) has been identified in patients from several families with familial Alzheimer's disease. See, A. Goate et al.,
Nature
349, p. 704 (1991).
SUMMARY OF THE INVENTION
In the applicants' work, analysis of DNA from a family with autopsy-proven Alzheimer's disease revealed a single amino acid substitution (phenylalanine for valine) in the transmembrane domain of the amyloid precursor protein. This substitution is caused by a point mutation at nucleotide position 1924 (using the APP695 transcript) of the gene encoding the amyloid precursor protein in which guanine (normal) is replaced by thymine (mutant). This mutation correlated with the presence of Alzheimer's disease in all studied patients. Accordingly, one embodiment of the invention relates to a method for screening for risk of Alzheimer's disease in a patient. The method includes the step of assaying for a guanine to thymine point mutation at position 1924 of the patient's gene encoding the amyloid precursor protein.
The applicants' discovery also provides access to transgenic non-human mammals, preferably rodents such as mice, harboring an expressable gene sequence encoding human amyloid precursor protein having a phenyalanine for valine amino acid substitution in the transmembrane domain of the amyloid precursor protein. Access is also provided to vectors containing the above-noted gene sequence which can be used to create transgenics for study or protein expression (i.e. for production and recovery), and to the above-noted mutant amyloid precursor protein( with the phenylalanine for valine substitution) in substantially pure form.
Additional objects, advantages and embodiments of the invention will be apparent from the following description and appended claims.
REFERENCES:
patent: 4736866 (1988-04-01), Leder et al.
patent: 4965190 (1990-10-01), Woo et al.
patent: 5220013 (1993-06-01), Ponte et al.
patent: 5234814 (1993-08-01), Card et al.
patent: 5387742 (1995-02-01), Cordell
Selkoe (1991) Nature 354, 432-433.
Science, vol. 255, pp. 1200-1202, 1992.
Felsenstein et al (2995) Alz. Parkensons Disease, L, Hanea Ed., Plenum Press, NY. 401-409.
Games et al (1992) Neurokio. Aging 13, 569-576.
Podlisny et al (1992) Neurokio Aging 13, 561-567.
Secreted amyloid B-protein similar to that in the senile plagues of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease, Aug. 1996, Nature Medicine, vol. 2, No. 8, pp. 864-870.
Clinical characterisctics in a kindred with ealry-onset Alzheimer's disease and their linkage to a G-T change at position 2149 of the amyloid precursor protein gene, Nuerology 44, pp. 105-111, Jan. 1994.
Alzheimer-type neuropathology in transgenic mice overexpressing V717F B-amyloid precursor protein, Letters To Nature, vol. 373, pp. 523-527, Feb. 9, 1995.
Correlative Memory Deficits, AB Elevation, and Amyloid Plaques in Transgenic Mice, Science, vol. 274, pp. 99-102, Oct. 1996.
Transgenic Animals, Science, vol. 140, pp. 1468-1474, Jun. 1988.
Relation of Neuronal APP-755/APP-695 mRNA Ratio and Neuritic Plaque Density in Alzheimer's Disease, Science, vol. 248, pp. 854-857, May 1990.
Deposits of Amyloid B Protein in the Central Nervous System of Transgenic Mice, Science, vol. 253, pp. 323-326, Jul. 19, 1991.
Formation of B-amyloid protein deposits in brains of transgenic mice, Nature, vol. 352, pp. 239-241, Jul. 18, 1991.
Proteolytical processing of mutated human amyloid precursor protein in transgenic mice, Molecular Brain Research 47, 108-116, Feb. 1997.
Somatic Expression of herpes Thymidine Kinase in Mice following Injection of a Fusion Gene into Eggs, Cell, vol. 27, 223-31, Nov. 1981.
Introduction of a rabbit B-globin gene into the mouse germ line, Nature, vol. 294, pp. 92-94.
Factors affecting the efficiency of introducing foreign DNA into mice by microinjecting eggs, Proc. Natl. Acad. Sci. USA, vol. 82, pp. 4438-4442.
A Foreign B-Globin Gene in Tranagenic Mice Integration at Abnormal Chromosomal Positions and Expression in Inappropriate Tissues, Cell 34, pp. 343-58, 1983.
Minireview: Creating Animal Models of Genetic Disease, Am. J. Hum. Genet. 43, pp. 582-586, 1988.
Alzheimer's Disease: A Cell Biological Perspective, Science, vol. 256, pp. 780-783, May 8, 1992.
Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease, Nature, vol. 349, pp. 704-706, Feb. 21, 1991.
PDGF B-Chain in Neurons of the Central Nervous System, Posterior Pituitary, and in a Transgenic Model, Cell, vol. 64, 217-27, Jan. 11, 1991.
Transgenic Mice Expressing Hamster Prion Protein Produce Species-Specific Scrapie Infectivity and Amyloid Plaques, Cell, vol. 59, pp. 847-857, Dec. 1, 1989.
Expression of the Human B-Amyloid Protein of Alzheimer's Disease Specifically in the Brains of Transgenic Mice, The Journal of Biological Chemistry, vol. 266, No. 32, pp. 21331-21334, Nov. 16, 1991.
Benson Merrill D.
Farlow Martin
Ghetti Bernardino
Murrell Jill
Advanced Research and Technology Institute
Crouch Deborah
Woodard Emhardt Naughton Moriarty & McNett
LandOfFree
Transgenic mouse expressing APP770-V717F does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Transgenic mouse expressing APP770-V717F, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Transgenic mouse expressing APP770-V717F will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2605537